L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma

• Published in: PloS one 2013-11, Vol.8 (11), p.e80088-e80088
• Main Authors: Mori, Naoki, Ohwashi, Mari, Yoshinaga, Kentaro, Mitsuhashi, Kenjiro, Tanaka, Norina, Teramura, Masanao, Okada, Michiko, Shiseki, Masayuki, Tanaka, Junji, Motoji, Toshiko
• Format: Article
• Language: English
• Subjects: Adult; Aged; Alleles; B-cell lymphoma; Bone marrow; Cloning; Digestion; Disease; Female; Females; Genotype; Hematology; Humans; Immunoglobulin G; Immunoglobulin M; Incidence; Leukemia; Leukocytes (mononuclear); Lymphocytes B; Lymphoma; Lymphoma - genetics; Lymphomas; Macroglobulinemia; Male; Males; Medical prognosis; Middle Aged; Multiple myeloma; Multiple Myeloma - genetics; Mutation; MyD88 protein; Myeloid Differentiation Factor 88 - genetics; Myeloma; Neoplasms; Patients; Phosphorylation; Polymerase Chain Reaction; Proteins; Tumors; Waldenstrom Macroglobulinemia - genetics; Womens health
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0080088

L265P mutation in the MYD88 gene has recently been reported in Waldenström's macroglobulinemia; however the incidence has been different according to the methods used. To determine the relevance and compare the incidence by different methods, we analyzed the L265P mutation in bone marrow mononuclear cells from lymphoid neoplasms. We first performed cloning and sequencing in 10 patients: 8 Waldenström's macroglobulinemia; 1 non-IgM-secreting lymphoplasmacytic lymphoma; and 1 low grade B-cell lymphoma with monoclonal IgG protein. The L265P mutation was detected in only 1/8 Waldenström's macroglobulinemia patients (2 of 9 clones). To confirm these results, direct sequencing was performed in the 10 patients and an additional 17 Waldenström's macroglobulinemia patients and 1 lymphoplasmacytic lymphoma patient. Nine of 28 patients (7/25 Waldenström's macroglobulinemia, 1/2 lymphoplasmacytic lymphoma, and B-cell lymphoma) harbored the mutation. We next tested for the mutation with BSiE1 digestion and allele-specific polymerase chain reaction in the 28 patients and 38 patients with myeloma. Aberrant bands corresponding to the mutation were detected by BSiE1 digestion in 19/25 patients with Waldenström's macroglobulinemia (76%), 1/2 lymphoplasmacytic lymphoma and B-cell lymphoma, but not in the 38 myeloma patients. The L265P mutation was more frequent in patients with Waldenström's macroglobulinemia than in those with myeloma (p=1.3x10(-10)). The mutation was detected by allele-specific polymerase chain reaction in 18/25 Waldenström's macroglobulinemia patients (72%). In the 25 Waldenström's macroglobulinemia patients, the L265P was more frequently detected by BSiE1 digestion than by direct sequencing (p=5.3x10(-4)), and in males (15/16, 94%) than in females (4/9, 44%) (p=1.2x10(-2)). No siginificant difference was observed in the incidence of the L265P mutation between BSiE1 digestion and allele-specific polymerase chain reaction (p=0.32). These results suggest that the L265P mutation is involved in the majority of Waldenström's macroglobulinemia. BSiE1 digestion and allele-specific polymerase chain reaction may detect a small fraction of mutated cells in some cases.